
Verastem, Inc. (NASDAQ:VSTM - Free Report) - Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Verastem in a research report issued to clients and investors on Tuesday, June 24th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the biopharmaceutical company will post earnings per share of ($3.57) for the year, down from their previous estimate of ($3.24). The consensus estimate for Verastem's current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Verastem's FY2026 earnings at ($3.69) EPS.
Several other brokerages have also issued reports on VSTM. HC Wainwright increased their price objective on Verastem from $10.00 to $14.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Guggenheim increased their target price on shares of Verastem from $13.00 to $14.00 and gave the stock a "buy" rating in a research report on Monday, March 24th. Jefferies Financial Group began coverage on shares of Verastem in a research report on Thursday, April 10th. They set a "buy" rating and a $15.00 target price on the stock. Mizuho lowered their target price on shares of Verastem from $9.00 to $8.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Finally, Royal Bank Of Canada raised shares of Verastem from an "outperform" rating to a "moderate buy" rating and lowered their target price for the stock from $16.00 to $12.00 in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $13.38.
View Our Latest Research Report on VSTM
Verastem Stock Down 0.2%
Shares of NASDAQ:VSTM traded down $0.01 during midday trading on Thursday, hitting $4.15. 5,151,438 shares of the stock were exchanged, compared to its average volume of 1,225,691. The company has a debt-to-equity ratio of 2.77, a quick ratio of 3.50 and a current ratio of 3.50. Verastem has a 52-week low of $2.10 and a 52-week high of $9.10. The business's fifty day simple moving average is $6.61 and its two-hundred day simple moving average is $5.99. The company has a market capitalization of $228.04 million, a PE ratio of -1.30 and a beta of 0.85.
Verastem (NASDAQ:VSTM - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.24).
Insider Activity
In other news, CEO Dan Paterson sold 58,677 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.13, for a total value of $477,044.01. Following the sale, the chief executive officer now directly owns 461,982 shares of the company's stock, valued at approximately $3,755,913.66. This trade represents a 11.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Daniel Calkins sold 11,143 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.13, for a total value of $90,592.59. Following the completion of the sale, the chief financial officer now directly owns 114,055 shares in the company, valued at approximately $927,267.15. This represents a 8.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 93,796 shares of company stock valued at $693,033. 2.10% of the stock is owned by insiders.
Institutional Investors Weigh In On Verastem
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. grew its position in Verastem by 236.9% during the first quarter. Goldman Sachs Group Inc. now owns 756,402 shares of the biopharmaceutical company's stock worth $4,561,000 after buying an additional 531,873 shares in the last quarter. Rhumbline Advisers grew its position in Verastem by 32.8% during the first quarter. Rhumbline Advisers now owns 49,959 shares of the biopharmaceutical company's stock worth $301,000 after buying an additional 12,330 shares in the last quarter. Octagon Capital Advisors LP acquired a new stake in Verastem during the first quarter worth about $10,372,000. Polar Asset Management Partners Inc. acquired a new stake in Verastem during the first quarter worth about $300,000. Finally, AQR Capital Management LLC grew its position in Verastem by 78.2% during the first quarter. AQR Capital Management LLC now owns 62,603 shares of the biopharmaceutical company's stock worth $377,000 after buying an additional 27,477 shares in the last quarter. 88.37% of the stock is owned by institutional investors and hedge funds.
About Verastem
(
Get Free Report)
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Recommended Stories

Before you consider Verastem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verastem wasn't on the list.
While Verastem currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.